Evidence map›Paper›PMID 31857697›Full record

ReviewLaboratory investigation; a journal of technical methods and pathology2020

TRPV2 channel as a possible drug target for the treatment of heart failure.

Yuko Iwata, Shin Ito, Shigeo Wakabayashi, Masafumi Kitakaze

Open access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Laboratory investigation; a journal of technical methods and pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.8field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Role of TRP Channels in Metabolism-Related Diseases.International journal of molecular sciences · 2024
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Yuko IwataDepartment of Clinical Research and Development, National Cerebral and Cardiovascular Center, Suita, Japan. yukoiwat@ncvc.go.jp.
Shin ItoDepartment of Clinical Research and Development, National Cerebral and Cardiovascular Center, Suita, Japan.
Shigeo WakabayashiDepartment of Pharmacology, Osaka Medical Collage, Takatsuki, Osaka, Japan.
Masafumi KitakazeDepartment of Clinical Research and Development, National Cerebral and Cardiovascular Center, Suita, Japan.
National Cerebral and Cardiovascular Center · JPOsaka Medical and Pharmaceutical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart transplantation is currently the only viable option available for the treatment of severe heart failure conditions such as dilated cardiomyopathy. Hence, novel drugs for treating such conditions need to be developed urgently. Recent studies suggest that Ca

Indexed as

Cardiovascular AgentsTRPV Cation ChannelsAnimalsCalcium ChannelsDrug DevelopmentHeart FailureHumansMiceMyocytes, CardiacCalcium ChannelsCardiovascular AgentsTRPV2 protein, humanTrpv2 protein, mouseTRPV Cation Channels

Identifiers

PMID31857697
OpenAlexW2996733876

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.